ArticleStroke2026
SLAMF1 as a Risk Biomarker for Nontraumatic SAH: Evidence From a Multiomics Study.
Article in Stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSubarachnoid hemorrhage (SAH) following aneurysmal rupture remains a devastating cerebrovascular event with limited predictive biomarkers. Accurate prediction of aneurysm rupture risk remains a clinical priority, as it could improve risk prediction and reveal potential therapeutic targets. Leveraging UK Biobank proteomic data, we aimed to identify protein markers associated with SAH risk using observational and genetic analyses.
methodsWe analyzed data from 52 916 participants enrolled in the UK Biobank. The analysis involved 3 steps: (1) Longitudinal cox proportional hazards analyses between normalized circulating levels of 2923 proteins and incident nontraumatic SAH (aneurysmal or nonaneurysmal) adjusting for age, sex, ancestry, smoking status, hypertension, hyperlipidemia, and diabetes; (2) Proteins identified in step 1 (false discovery rate-adjusted
resultsWe identified 123 incident SAH cases; the mean follow-up was 7.06 years (SD, 3.53), the mean age was 59.28 (SD, 7.13), and 62% were females. SLAMF1 (signaling lymphocytic activation molecule family member 1) and NINJ1 (Ninjurin 1) were significantly associated (SLAMF1: HR per SD increase, 2.18 [95% CI, 1.49-3.18]; adjusted
conclusionsOur combined analytical approach identified SLAMF1 as a protein associated with increased SAH risk. SLAMF1, a receptor involved in modulating innate and adaptive immune responses, has been implicated in inflammatory and autoimmune diseases. SLAMF1 and related proteins represent promising biomarkers for SAH risk, potentially enhancing risk stratification, guiding preventive strategies, and informing future therapeutic development. Further research is necessary to explore its mechanistic role in SAH development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.